Screening for Prognostic Biomarkers of Severe Bell's Palsy in Adults Using Proteomic Analysis by Quantitative Mass Spectroscopy

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

Bell's palsy (idiopathic peripheral facial palsy) is the most common cause of facial palsy, which is related to the inflammation of the facial nerve, possibly induced by herpesvirus reactivation. Its first-line treatment comprises corticosteroids, antiviral therapy and physiotherapy. In most severe cases (grade IV to VI on House-Brackmann scale), facial motricity may remain altered or develop synkinesis or post-paralytic spasm, thus tremendously affecting quality of life. To avoid potential complications, surgical facial nerve decompression could be proposed. To date, however, there are no means to predict if Bell's palsy will evolve with any complications or if the patient will recover entirely. Thus, the invasive facial nerve decompression is equally proposed to subjects who will develop the consequences as well as to subjects able to restore without surgical treatment. This study proposes to search for prognostic blood biomarkers related to the Bell's palsy recovery pattern. Adult patients with severe Bell's palsy will be proposed to have a blood sampling for proteomic analysis in the early stage of the disease. Then 125 biomarkers on a Peptiquant™ kit will be analysed by mass spectrometry, and prognostic biomarkers will be selected regarding to the clinical recovery of Bell's palsy

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Severe Bell's palsy (House-Brackmann more or equal to IV)

• Disease developed between 5 and 15 days before V0 (after initial corticotherapy)

• 18 years and older

Locations
Other Locations
France
CHU Montpellier
RECRUITING
Montpellier
Contact Information
Primary
Anne-Lise Fourez, MD
al-fourez@chu-montpellier.fr
+334 67 33 68 90
Backup
Frédéric Venail, MD, PhD
f-venail@chu-montpellier.fr
+334 67 33 68 90
Time Frame
Start Date: 2023-01-03
Estimated Completion Date: 2026-07
Participants
Target number of participants: 130
Treatments
Adult patients with severe Bell's palsy
Adult patients recently diagnosed with severe Bell's palsy and referred to the ENT Department by A\&E or by general practitionner.
Sponsors
Leads: University Hospital, Montpellier

This content was sourced from clinicaltrials.gov